Literature DB >> 18060937

Combination therapy for treatment of osteoporosis: A review.

Joann V Pinkerton1, Alan C Dalkin.   

Abstract

Combination therapy for osteoporosis has been tested in small trials of short duration with various combinations. Pertinent human and animal randomized clinical trial data were identified through Medline and reviewed with a focus on the risks and benefits of different types of combination therapies. Improvements in bone density were found in some, but not all, combinations. There are no large trials of adequate length or numbers to determine fracture efficacy. Consider combination therapy if monotherapy is unsuccessful, if there is an added nonskeletal benefit to the proposed combination or as sequential treatment with an anabolic agent followed by an antiresorptive agent. Although combination therapy, in general, has limitations based on cost, concern about potential oversuppression of bone, and lack of long-term safety and fracture efficacy, selected patients may benefit.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060937     DOI: 10.1016/j.ajog.2007.07.022

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  An osteoclast-targeting agent for imaging and therapy of bone metastasis.

Authors:  Wei Liu; Asghar Hajibeigi; Mai Lin; Cynthia L Rostollan; Zoltan Kovacs; Orhan K Oz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2008-07-27       Impact factor: 2.823

2.  Complexation Hydrogels for the Oral Delivery of Growth Hormone and Salmon Calcitonin.

Authors:  Daniel A Carr; Marta Gómez-Burgaz; Mathilde C Boudes; Nicholas A Peppas
Journal:  Ind Eng Chem Res       Date:  2010-09-29       Impact factor: 3.720

3.  Impact of Absorption and Transport on Intelligent Therapeutics and Nano-scale Delivery of Protein Therapeutic Agents.

Authors:  Nicholas A Peppas; Daniel A Carr
Journal:  Chem Eng Sci       Date:  2009-11-16       Impact factor: 4.311

4.  Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.

Authors:  Enrico M Messalli; Cono Scaffa
Journal:  Int J Womens Health       Date:  2010-08-09

5.  Indirect regulation of PTH by estrogens may require FGF23.

Authors:  Natalia Carrillo-López; Pablo Román-García; Ana Rodríguez-Rebollar; José Luis Fernández-Martín; Manuel Naves-Díaz; Jorge B Cannata-Andía
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

Review 6.  Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives.

Authors:  Xiao Lin; Dan Xiong; Yi-Qun Peng; Zhi-Feng Sheng; Xi-Yu Wu; Xian-Ping Wu; Feng Wu; Ling-Qing Yuan; Er-Yuan Liao
Journal:  Clin Interv Aging       Date:  2015-06-25       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.